Qiming Venture Partners Backed Structure Therapeutics Successfully Debuts on Nasdaq

Rhea-AI Summary

Structure Therapeutics Inc. (NASDAQ: GPCR), backed by Qiming Venture Partners, successfully debuted on Nasdaq on February 3, 2023. Issued at $15.00 per ADS, it opened at $25.00, marking a 66.67% increase and a market cap of $915 million. Qiming Venture Partners has been an early investor since 2019. Structure Therapeutics focuses on converting biologics into orally available small molecules, targeting G-protein-coupled receptors. Their pipeline includes GSBR-1290 for type-2 diabetes and ANPA-0073 for pulmonary conditions, with significant studies completed in September 2022.

Positive

• Structure Therapeutics IPO raised $915 million in market cap.
• Stock opened 66.67% above the issue price, indicating strong market interest.
• Innovative drug development platform targeting critical health issues.

Negative

• None.

SHANGHAI, Feb. 4, 2023 /PRNewswire/ -- Qiming Venture Partners' portfolio company Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical stage global biopharmaceutical company focusing on novel oral small molecule therapeutics, successfully debuts on Nasdaq on February 3 Beijing Time. It issued at $15.00 per ADS, opened at $25.00 per ADS and up by 66.67%, representing a market cap of $915 million.

As an early investor, Qiming first invested in the company's series A round in 2019 and continued to participate in its A+ and B rounds. This successful IPO also marks Qiming's second IPO in 2023.

Co-founded by Raymond Stevens, Ph.D., a world-renowned pioneer in the field of structure-based drug discovery, and another Qiming's portfolio company Schrödinger, a leading player in computational physics-based drug design, Structure Therapeutics' platform enables conversion of biologics and peptide therapeutics into orally available small molecule drugs with enhanced pharmaceutical properties, including improved bioavailability and stability by leveraging structure-based drug discovery and computational chemistry expertise.

Targeting G-protein-coupled receptors, or GPCRs, Structure Therapeutics currently has a wholly owned pipeline of candidates, including GSBR-1290 targeting GLP-1R, for the treatment of type-2 diabetes mellitus, or T2DM, and obesity, with Phase 1 single ascending dose, or SAD study completed in September 2022, and next generation GLP-1R candidates designed with customized properties to achieve additional benefit. In September 2022, the company completed a Phase 1 SAD and MAD study evaluating ANPA-0073 targeting the apelin receptor, or APJR, for the treatment of patients with diopathic pulmonary fibrosis, or IPF, and pulmonary arterial hypertension, or PAH. It is also advancing a differentiated lysophosphatidic acid 1 receptor, or LPA1R, antagonist for the treatment of IPF.

"We are pleased to have been one of the earliest investors and accompanied Structure Therapeutics all the way to the IPO today, a new milestone for the company", said Nisa Leung, Managing Partner of Qiming Venture Partners, "Ever since its inception, Structure Therapeutics has adopted an innovative approach to address current challenges and built a platform to find the best drug candidates. With a global team of experts and their decades of experience, we look forward to Structure Therapeutics further advancing product R&D, commercialization, and corporate development to produce better and more affordable medicines, addressing global unmet needs."

About Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.

Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi (SEHK:1810), Meituan (SEHK:3690), Bilibili (NASDAQ:BILI, SEHK:9626), Zhihu (NYSE: ZH, SEHK: 2390), Roborock (SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087), Tigermed (SZSE:300347, SEHK:3347), Zai Lab (NASDAQ:ZLAB, SEHK:9688), CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger (NASDAQ:SDGR), APT Medical (SHSE:688617), New Horizon Health (SEHK:6606), Venus MedTech (SEHK:2500), Sanyou Medical (SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710), SinocellTech (SHSE: 688520), Yuanxin Technology, Caidya, Belief BioMed, WeRide, Biren Technology and UBTech among many others.

View original content:https://www.prnewswire.com/news-releases/qiming-venture-partners-backed-structure-therapeutics-successfully-debuts-on-nasdaq-301738824.html

SOURCE Qiming Venture Partners

FAQ

What is the significance of Structure Therapeutics' IPO on February 3, 2023?

Structure Therapeutics' IPO allowed the company to achieve a market cap of $915 million, with shares opening at $25.00, reflecting strong demand.

What drug candidates does Structure Therapeutics have in its pipeline?

Structure Therapeutics is advancing GSBR-1290 for type-2 diabetes and ANPA-0073 for pulmonary diseases, among others.

How much did Structure Therapeutics raise during its IPO?

Structure Therapeutics debuted with a market valuation of $915 million after its IPO, which was issued at $15.00 per ADS.

Who are the main investors in Structure Therapeutics?

Qiming Venture Partners has been a key investor in Structure Therapeutics since its Series A round in 2019.

What is the focus of Structure Therapeutics in drug development?

Structure Therapeutics focuses on converting biologics into orally available small molecule drugs targeting G-protein-coupled receptors.